{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:20:13Z","timestamp":1789503613428,"version":"build-2803163510"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,4,1]]},"DOI":"10.1001\/jamaoncol.2019.6276","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T16:31:04Z","timestamp":1580401864000},"page":"528","source":"Crossref","is-referenced-by-count":25,"title":["High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes"],"prefix":"10.1001","volume":"6","author":[{"given":"Tessa G.","family":"Steenbruggen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars C.","family":"Steggink","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Seynaeve","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus J. M.","family":"van der Hoeven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge R.","family":"Konings","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, location VUmc, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim M.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Medical Oncology, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne C. G.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsken","family":"van der Wall","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan D.","family":"Bins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, location AMC, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine C.","family":"Linn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaapveld","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy N.","family":"Jacobse","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien P.","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, the Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G. E.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jourik A.","family":"Gietema","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"coi190108r1","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1200\/JCO.2010.32.5910","article-title":"High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.","volume":"29","author":"Berry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190108r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMoa022794","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.","volume":"349","author":"Rodenhuis","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"coi190108r3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1093\/annonc\/mdl001","article-title":"Efficacy of high-dose alkylating chemotherapy in HER2\/neu\u2013negative breast cancer.","volume":"17","author":"Rodenhuis","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"coi190108r4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1023\/A:1008390203340","article-title":"Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.","volume":"10","author":"Basser","year":"1999","journal-title":"Ann Oncol"},{"issue":"5","key":"coi190108r5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"coi190108r6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMoa030684","article-title":"Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.","volume":"349","author":"Tallman","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"coi190108r7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/cncr.v106:11","article-title":"Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.","volume":"106","author":"Hanrahan","year":"2006","journal-title":"Cancer"},{"issue":"14","key":"coi190108r8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/jnci\/djh188","article-title":"Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.","volume":"96","author":"Leonard","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"9501","key":"coi190108r9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0140-6736(05)67784-7","article-title":"Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.","volume":"366","author":"Nitz","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"coi190108r10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/annonc\/mdi166","article-title":"High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.","volume":"16","author":"Coombes","year":"2005","journal-title":"Ann Oncol"},{"issue":"10","key":"coi190108r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1200\/JCO.2005.10.202","article-title":"Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.","volume":"23","author":"Peters","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi190108r12","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.2001.19.10.2746","article-title":"Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.","volume":"19","author":"Meinardi","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9239","key":"coi190108r13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0140-6736(00)02841-5","article-title":"Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial: Scandinavian Breast Group 9401 study.","volume":"356","author":"Bergh","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"coi190108r14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/annonc\/mdl488","article-title":"Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.","volume":"18","author":"Wilking","year":"2007","journal-title":"Ann Oncol"},{"issue":"9","key":"coi190108r15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V.","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi190108r16","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"coi190108r17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/jnci\/92.3.225","article-title":"Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.","volume":"92","author":"Hortobagyi","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"9114","key":"coi190108r18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials: Early Breast Cancer Trialists\u2019 Collaborative Group.","volume":"351","author":"EBCTCG","year":"1998","journal-title":"Lancet"},{"issue":"15","key":"coi190108r19","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi190108r20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/annonc\/mdp024","article-title":"The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.","volume":"20","author":"Colleoni","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"coi190108r21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/107327480301000105","article-title":"High-dose chemotherapy for breast cancer: the French PEGASE experience.","volume":"10","author":"Roche","year":"2003","journal-title":"Cancer Control"},{"issue":"10","key":"coi190108r23","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO\u2014magnitude of clinical benefit scale version 1.1.","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"coi190108r24","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy.","volume":"32","author":"Cameron","year":"2016","journal-title":"Can J Cardiol"},{"issue":"3","key":"coi190108r25","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3655","article-title":"Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.","volume":"16","author":"Vollebergh","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7","key":"coi190108r26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"coi190108r27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ijc.30078","article-title":"BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.","volume":"139","author":"Schouten","year":"2016","journal-title":"Int J Cancer"},{"key":"coi190108r22","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195187762.001.0001","volume-title":"False Hope: Bone Marrow Transplantation for Breast Cancer","author":"Rettig","year":"2007"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2759198\/jamaoncology_steenbruggen_2020_oi_190108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:38:11Z","timestamp":1722375491000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2759198"}},"subtitle":["20-Year Follow-up of a Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.6276","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}